BYSI
BeyondSpring Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.51
−8.28%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.55
From 52W high−78.17%
Volume32371.00
Market cap$21.09M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.55
From 52W high
−78.17%
Volume
32371.00
Market cap
$21.09M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
35.3
MomentumView details →
1D Return
−8.28%
YTD Return
−67.42%
SummaryUpdated Jun 1, 2026
BeyondSpring Inc. (NASDAQ:BYSI) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in New York, New York. The company went public in March 2017 and focuses on developing innovative cancer therapies, particularly targeting chemotherapy-induced side effects and various forms of lung cancer. BeyondSpring's primary asset is Plinabulin, a novel drug that has completed Phase III clinical trials and represents the company's main pathway to potential commercialization and revenue generation.
Similar companies
Latest newsMore news →
BeyondSpring Inc. received a Nasdaq notice dated September 29, 2026 that it no longer meets the $35 million minimum market value of listed securities requirement under Rule 5550(b)(2), giving it until March 29, 2027 to regain compliance.17d agoThe U.S. Food and Drug Administration granted Fast Track designation to BeyondSpring's Plinabulin plus docetaxel for advanced or metastatic non-squamous NSCLC without actionable genomic alterations that progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy.21d agoBeyondSpring Inc. received a NASDAQ notice dated September 17, 2026 that it no longer complies with the $1.00 minimum bid price requirement under Rule 5550(a)(2), giving it until March 16, 2027 to regain compliance.31d ago